US tariffs mainly target branded and patented drugs, where multinational companies like Pfizer Inc. and Novo Nordisk Inc. dominate. (Photo: Freepik) Show Quick Read Summary is AI Generated. Newsroom Reviewed

The Trump administration will impose a 100% import tariff starting Oct. 1 on branded or patented drugs unless a company has or is building a manufacturing plant in the US. This presents a fresh challenge to Indian pharmaceutical companies.

The US is the largest market for Indian drugmakers. India exported $3.7 billion worth of pharma products to the US in the first half of 2025.

In a post on Truth Social, President Donald Trump said, "Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING the

See Full Page